Aging Options

LIMITED TIME OFFER: First Academy Lesson is Free

Experimental drug study slows cognitive decline in some Alzheimer's cases

Save as PDF

Eli Lilly and Company announced Oct. 8 that a second look at an experimental drug therapy called solanezumab that targets mild to moderate Alzheimer’s disease, found the cognitive decline in study participants slowed by 34 percent.  A full report and study results can be found here.

Need assistance planning for your successful retirement? Give us a call! 1.877.762.4464

Learn how 70% of retirement plan fails and find out how you can avoid this

Find out more about LifePlanning

Your Cart is empty!

It looks like you haven't added any items to your cart yet.

Browse Products
Powered by Caddy
Skip to content